Qiagen N.V. (QGEN) 26.66 $QGEN Services Stocks
Post# of 273330
Posted On: 09/25/2016 3:12:09 PM
Qiagen N.V. (QGEN) 26.66 $QGEN
Services Stocks on Investors' Radar -- HERC, Myriad Genetics, Qiagen, and INC Research
PR Newswire - Wed Sep 21, 6:30AM CDT
Today, Stock-Callers reviews the performance of these services stocks: HERC Holdings Inc. (NYSE: HRI), Myriad Genetics Inc. (NASDAQ: MYGN), Qiagen NV (NASDAQ: QGEN), and INC Research Holdings Inc. (NASDAQ: INCR). At the close of Tuesday's trading session, the NASDAQ Composite ended the trading session at 5,241.35, up 0.12%; the Dow Jones Industrial Average edged 0.05% higher, to finish at 18,129.96; and the S&P 500 closed at 2,139.76, up 0.03%. Learn more about these stocks by accessing their free research reports at:
MYGN: 21.67 (+0.17), INCR: 44.94 (+0.54), HRI: 33.36 (+0.57), QGEN: 26.66 (-0.21)
Qiagen: Molecular Diagnostics & Expansion Plans on Track
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:14AM CDT
On Sep 13, 2016, we issued an updated research report on Qiagen NV (QGEN).
HSKA: 54.46 (-0.22), ANIP: 66.64 (-0.17), QGEN: 26.66 (-0.21), ANIK: 46.92 (-1.07)
After Yesterday's Decline of 1.61%, QIAGEN Offers Investors Better Value
Comtex SmarTrend(R) - Mon Sep 12, 1:31PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.30 to a high of $25.78. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $26.08 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
QGEN: 26.66 (-0.21)
Watch for QIAGEN to Potentially Rebound After Falling 1.61% Yesterday
Comtex SmarTrend(R) - Mon Sep 12, 1:29PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.30 to a high of $25.78. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $26.08 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
QGEN: 26.66 (-0.21)
QIAGEN Comments on Preliminary Injunction and Confirms Intention to Defend its U.S. Intellectual Property Position
PR Newswire - Sat Sep 10, 10:30AM CDT
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) commented on a decision issued late on Friday, September 9, by the U.S. District Court for the Northern District of California, San Francisco Division, in which the Court granted the motion for a preliminary injunction against the Company as part of patent litigation filed by a competitor. The lawsuit alleges infringement of U.S. Patent 7,566,537 by QIAGEN's GeneReader NGS System.
QGEN: 26.66 (-0.21)
QIAGEN Welcomes U.S. Guidance for Latent TB Testing in Primary Care
PR Newswire - Thu Sep 08, 11:46AM CDT
U.S. Preventive Services Task Force issues recommendations to screen high-risk patients
QGEN: 26.66 (-0.21)
QIAGEN Announces Plans to Return Approximately $250 Million to Shareholders Via Synthetic Share Repurchase Proposal
PR Newswire - Sun Aug 14, 7:48AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced plans to return approximately $250 million to shareholders through a synthetic share repurchase proposal that combines a direct capital repayment with a reverse stock split.
QGEN: 26.66 (-0.21)
Technical Roundup on Services Stocks -- Booz Allen Hamilton, Qiagen, Myriad Genetics, and INC Research
PR Newswire - Tue Aug 02, 9:22AM CDT
Stock-Callers.com redirects investors' attention to the Services sector, which as per U.S. Census Bureau, primarily consists of truck transportation, messenger services and warehousing; information sector services; securities, commodities and other financial investment services; rental and leasing services; health care and social assistance; etc. In focus are the following equities ahead of today's trading session: Booz Allen Hamilton Holding Corp. (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), Myriad Genetics Inc. (NASDAQ: MYGN), and INC Research Holdings Inc. (NASDAQ: INCR). Sign up today and download for free the research reports for the stocks covered today at:
MYGN: 21.67 (+0.17), BAH: 31.13 (-0.10), INCR: 44.94 (+0.54), QGEN: 26.66 (-0.21)
Upgrade Alert for QIAGEN (QGEN)
Comtex SmarTrend(R) - Tue Aug 02, 3:24AM CDT
QIAGEN (NASDAQ:QGEN) was upgraded from Hold to Buy at HSBC today. The stock closed yesterday at $26.80 on volume of 1.3 million shares, above average daily volume of 854,000. QIAGEN (NASDAQ:QGEN) defies analysts with a current price ($26.80) 2.4% above its average consensus price target of $26.15. The stock should find initial support at its 200-day moving average (MA) of $24.71 and further support at its 50-day MA of $22.38.
QGEN: 26.66 (-0.21)
Qiagen (QGEN) Tops Q2 Earnings & Sales; Margins Drop Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:08AM CDT
Qiagen (QGEN) ended the second-quarter 2016 on a promising note, squarely beating the Zacks Consensus Estimates.
BABY: 43.99 (-0.39), MASI: 59.77 (-0.55), CPHD: 52.50 (unch), QGEN: 26.66 (-0.21)
After Yesterday's Rally of 14.51% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jul 29, 2:15PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.35 to a high of $26.88. Yesterday, the shares gained 14.5%, which took the trading range above the 3-day high of $23.58 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
QGEN: 26.66 (-0.21)
QIAGEN Set to Possibly Pullback After Yesterday's Rally of 14.51%
Comtex SmarTrend(R) - Fri Jul 29, 2:13PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.35 to a high of $26.88. Yesterday, the shares gained 14.5%, which took the trading range above the 3-day high of $23.58 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
QGEN: 26.66 (-0.21)
QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017
PR Newswire - Thu Jul 28, 3:05PM CDT
-- Q2 2016 results show QIAGEN delivering on goals for acceleration during the year
QGEN: 26.66 (-0.21)
Bioinformatics Leaders to Discuss QIAGEN Biomedical Genomics Solution for NGS Researchers
PRWeb - Wed Jul 27, 9:17PM CDT
QIAGEN N.V. is sponsoring a new, free educational webinar titled "Reference Architectures for the QIAGEN Biomedical Genomics Solution." The conversation will feature joint discussion between key bioinformatics industry leaders and will be pertinent to NGS researchers who need to cost-effectively scale up their genome analysis workflows. The free webinar will be presented on August 2, 2016, at 8 am PT/11 am ET.
QGEN: 26.66 (-0.21)
QIAGEN Launches "Digital NGS" Solutions with Unique Molecular Index Technology to Reliably Detect All Genetic Variation
PR Newswire - Wed Jul 27, 3:07PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of a comprehensive portfolio of novel QIAseq NGS panels based on a new and proprietary "Digital NGS" technology allowing unbiased, accurate quantification of DNA, RNA and miRNA with next-generation sequencing (NGS). Digital NGS leverages a novel unique Molecular Index Technology enabling more accurate quantification and detection of molecular variants across all sequencing platforms.
QGEN: 26.66 (-0.21)
QIAGEN Launches Novel Integrated System for Collection, Stabilization, Transport, Storage and Isolation of Circulating Cell-free DNA
PR Newswire - Wed Jul 27, 3:05PM CDT
PAXgene Blood ccfDNA enhances handling and workflow convenience for liquid biopsy applications in prenatal testing and cancer research
QGEN: 26.66 (-0.21)
QIAGEN Announces Successful Completion of Tender Offer for Shares in Exiqon
PR Newswire - Thu Jun 23, 4:45AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the successful completion of the conditional, voluntary public tender offer for the shares in Exiqon A/S, a world leader in RNA technology. The extended Offer Period expired yesterday, on 22 June 2016, at 23.59 (CET).
QGEN: 26.66 (-0.21)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 23.71 (-0.02), BAX: 47.49 (-0.71), LMAT: 20.19 (-0.39), QGEN: 26.66 (-0.21)
Active Equities to Watch in the Services Sector -- Booz Allen Hamilton Holding, Qiagen, INC Research Holdings, and Myriad Genetics
PR Newswire - Fri Jun 17, 7:20AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Booz Allen Hamilton Holding Corporation (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), INC Research Holdings Inc. (NASDAQ: INCR), and Myriad Genetics Inc. (NASDAQ: MYGN). Learn more about these stocks by accessing their free trade alerts at:
MYGN: 21.67 (+0.17), BAH: 31.13 (-0.10), INCR: 44.94 (+0.54), QGEN: 26.66 (-0.21)
Services Stocks on Investors' Radar -- HERC, Myriad Genetics, Qiagen, and INC Research
PR Newswire - Wed Sep 21, 6:30AM CDT
Today, Stock-Callers reviews the performance of these services stocks: HERC Holdings Inc. (NYSE: HRI), Myriad Genetics Inc. (NASDAQ: MYGN), Qiagen NV (NASDAQ: QGEN), and INC Research Holdings Inc. (NASDAQ: INCR). At the close of Tuesday's trading session, the NASDAQ Composite ended the trading session at 5,241.35, up 0.12%; the Dow Jones Industrial Average edged 0.05% higher, to finish at 18,129.96; and the S&P 500 closed at 2,139.76, up 0.03%. Learn more about these stocks by accessing their free research reports at:
MYGN: 21.67 (+0.17), INCR: 44.94 (+0.54), HRI: 33.36 (+0.57), QGEN: 26.66 (-0.21)
Qiagen: Molecular Diagnostics & Expansion Plans on Track
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:14AM CDT
On Sep 13, 2016, we issued an updated research report on Qiagen NV (QGEN).
HSKA: 54.46 (-0.22), ANIP: 66.64 (-0.17), QGEN: 26.66 (-0.21), ANIK: 46.92 (-1.07)
After Yesterday's Decline of 1.61%, QIAGEN Offers Investors Better Value
Comtex SmarTrend(R) - Mon Sep 12, 1:31PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.30 to a high of $25.78. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $26.08 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
QGEN: 26.66 (-0.21)
Watch for QIAGEN to Potentially Rebound After Falling 1.61% Yesterday
Comtex SmarTrend(R) - Mon Sep 12, 1:29PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.30 to a high of $25.78. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $26.08 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
QGEN: 26.66 (-0.21)
QIAGEN Comments on Preliminary Injunction and Confirms Intention to Defend its U.S. Intellectual Property Position
PR Newswire - Sat Sep 10, 10:30AM CDT
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) commented on a decision issued late on Friday, September 9, by the U.S. District Court for the Northern District of California, San Francisco Division, in which the Court granted the motion for a preliminary injunction against the Company as part of patent litigation filed by a competitor. The lawsuit alleges infringement of U.S. Patent 7,566,537 by QIAGEN's GeneReader NGS System.
QGEN: 26.66 (-0.21)
QIAGEN Welcomes U.S. Guidance for Latent TB Testing in Primary Care
PR Newswire - Thu Sep 08, 11:46AM CDT
U.S. Preventive Services Task Force issues recommendations to screen high-risk patients
QGEN: 26.66 (-0.21)
QIAGEN Announces Plans to Return Approximately $250 Million to Shareholders Via Synthetic Share Repurchase Proposal
PR Newswire - Sun Aug 14, 7:48AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced plans to return approximately $250 million to shareholders through a synthetic share repurchase proposal that combines a direct capital repayment with a reverse stock split.
QGEN: 26.66 (-0.21)
Technical Roundup on Services Stocks -- Booz Allen Hamilton, Qiagen, Myriad Genetics, and INC Research
PR Newswire - Tue Aug 02, 9:22AM CDT
Stock-Callers.com redirects investors' attention to the Services sector, which as per U.S. Census Bureau, primarily consists of truck transportation, messenger services and warehousing; information sector services; securities, commodities and other financial investment services; rental and leasing services; health care and social assistance; etc. In focus are the following equities ahead of today's trading session: Booz Allen Hamilton Holding Corp. (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), Myriad Genetics Inc. (NASDAQ: MYGN), and INC Research Holdings Inc. (NASDAQ: INCR). Sign up today and download for free the research reports for the stocks covered today at:
MYGN: 21.67 (+0.17), BAH: 31.13 (-0.10), INCR: 44.94 (+0.54), QGEN: 26.66 (-0.21)
Upgrade Alert for QIAGEN (QGEN)
Comtex SmarTrend(R) - Tue Aug 02, 3:24AM CDT
QIAGEN (NASDAQ:QGEN) was upgraded from Hold to Buy at HSBC today. The stock closed yesterday at $26.80 on volume of 1.3 million shares, above average daily volume of 854,000. QIAGEN (NASDAQ:QGEN) defies analysts with a current price ($26.80) 2.4% above its average consensus price target of $26.15. The stock should find initial support at its 200-day moving average (MA) of $24.71 and further support at its 50-day MA of $22.38.
QGEN: 26.66 (-0.21)
Qiagen (QGEN) Tops Q2 Earnings & Sales; Margins Drop Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:08AM CDT
Qiagen (QGEN) ended the second-quarter 2016 on a promising note, squarely beating the Zacks Consensus Estimates.
BABY: 43.99 (-0.39), MASI: 59.77 (-0.55), CPHD: 52.50 (unch), QGEN: 26.66 (-0.21)
After Yesterday's Rally of 14.51% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jul 29, 2:15PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.35 to a high of $26.88. Yesterday, the shares gained 14.5%, which took the trading range above the 3-day high of $23.58 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
QGEN: 26.66 (-0.21)
QIAGEN Set to Possibly Pullback After Yesterday's Rally of 14.51%
Comtex SmarTrend(R) - Fri Jul 29, 2:13PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.35 to a high of $26.88. Yesterday, the shares gained 14.5%, which took the trading range above the 3-day high of $23.58 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
QGEN: 26.66 (-0.21)
QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017
PR Newswire - Thu Jul 28, 3:05PM CDT
-- Q2 2016 results show QIAGEN delivering on goals for acceleration during the year
QGEN: 26.66 (-0.21)
Bioinformatics Leaders to Discuss QIAGEN Biomedical Genomics Solution for NGS Researchers
PRWeb - Wed Jul 27, 9:17PM CDT
QIAGEN N.V. is sponsoring a new, free educational webinar titled "Reference Architectures for the QIAGEN Biomedical Genomics Solution." The conversation will feature joint discussion between key bioinformatics industry leaders and will be pertinent to NGS researchers who need to cost-effectively scale up their genome analysis workflows. The free webinar will be presented on August 2, 2016, at 8 am PT/11 am ET.
QGEN: 26.66 (-0.21)
QIAGEN Launches "Digital NGS" Solutions with Unique Molecular Index Technology to Reliably Detect All Genetic Variation
PR Newswire - Wed Jul 27, 3:07PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of a comprehensive portfolio of novel QIAseq NGS panels based on a new and proprietary "Digital NGS" technology allowing unbiased, accurate quantification of DNA, RNA and miRNA with next-generation sequencing (NGS). Digital NGS leverages a novel unique Molecular Index Technology enabling more accurate quantification and detection of molecular variants across all sequencing platforms.
QGEN: 26.66 (-0.21)
QIAGEN Launches Novel Integrated System for Collection, Stabilization, Transport, Storage and Isolation of Circulating Cell-free DNA
PR Newswire - Wed Jul 27, 3:05PM CDT
PAXgene Blood ccfDNA enhances handling and workflow convenience for liquid biopsy applications in prenatal testing and cancer research
QGEN: 26.66 (-0.21)
QIAGEN Announces Successful Completion of Tender Offer for Shares in Exiqon
PR Newswire - Thu Jun 23, 4:45AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the successful completion of the conditional, voluntary public tender offer for the shares in Exiqon A/S, a world leader in RNA technology. The extended Offer Period expired yesterday, on 22 June 2016, at 23.59 (CET).
QGEN: 26.66 (-0.21)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 23.71 (-0.02), BAX: 47.49 (-0.71), LMAT: 20.19 (-0.39), QGEN: 26.66 (-0.21)
Active Equities to Watch in the Services Sector -- Booz Allen Hamilton Holding, Qiagen, INC Research Holdings, and Myriad Genetics
PR Newswire - Fri Jun 17, 7:20AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Booz Allen Hamilton Holding Corporation (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), INC Research Holdings Inc. (NASDAQ: INCR), and Myriad Genetics Inc. (NASDAQ: MYGN). Learn more about these stocks by accessing their free trade alerts at:
MYGN: 21.67 (+0.17), BAH: 31.13 (-0.10), INCR: 44.94 (+0.54), QGEN: 26.66 (-0.21)
(0)
(0)